The Keys to Opening Access to Clinical Trials
Menée auprès de 1 664 médecins et à partir de données portant sur 205 743 patients atteints d'un cancer métastatique ou de stade avancé diagnostiqué entre 2011 et 2024, cette étude évalue le taux de participation à des essais cliniques puis démontre que des facteurs liés aux médecins et aux centres de soins ont un impact plus important dans ce taux de participation que les caractéristiques individuelles des patients
Clinical trials are the primary means through which we advance understanding of how to overcome illness. With regard to oncology trials, Balogh et al stated, “Today’s standard of care treatment emerged from yesterday’s clinical trials,” and Unger et al wrote, “…the best treatments are received in clinical trials, [and] clinical trials provide access to tomorrow’s treatment today.” Yet, despite stated willingness, the vast majority of adults who receive cancer treatment in the US do not participate in a clinical trial. For these and many other reasons—including shortening accrual duration, reducing premature closure of trials, speeding up decisions on success or failure, accelerating the evolution of standards of care, ensuring that trial populations are truly generalizable to the clinical treatment population—overcoming this stark reality presents one of the greatest prevailing opportunities to improve population-level oncology outcomes.
JAMA Network Open , éditorial en libre accès, 2026